Interestingly, anti-TIF1γ is the most common autoantibody seen in juvenile-onset IIM cohorts from the UK and USA, where it is not associated with malignancy but is linked to more severe skin disease and disease chronicity [4–7]. Here, TRIM33 is linked to cancer.